Position: Postdoctoral Fellowship Position

Research Area:

Mass Spectrometry, Proteomics, Post-translational Modifications, Lipoproteins, Lipid Biology, Inflammation, Cardiometabolic Diseases

Full/Part Time: Full Time

Investigator: Singh, Sasha A.

Date Posted: 2024-12-13

Description:

New avenues in lipoprotein research.

Project Summary:

We have an open position in the Proteomics Group led by Dr. Sasha A. Singh. The candidate will have the opportunity to establish a completely novel concept in lipoprotein biology that can impact clinical practices. The main project entails in vitro and in vivo studies on the biogenesis, secretion, and functional characterization of previously undescribed lipoproteins subspecies, and their impact on cardiometabolic disorders.

The candidate should have a solid skillset in molecular biology, cell biology, and biochemistry that are the minimum requirements to achieve study goals, and a strong track record in publications. Although beneficial, mass spectrometry experience is not a prerequisite, but the candidate must have a strong drive to learn about the technology since it is integral to the project. Experience in bioinformatics, systems biology and/or machine learning is also advantageous. We also expect an individual with outstanding motivation and a firm commitment to productivity. In order to lead the project to a successful completion, the candidate is encouraged to collaborate with other exceptional scientists at the center. Dr. Singh also collaborates with several labs world-wide, therefore there will be many opportunities to increase research scope and knowledge through these collaborations.

Research Environment:

The Proteomics lab is equipped with an Orbitrap Fusion Lumos (+ETD), an Orbitrap Exploris 480 (+ FAIMS Pro), and a PreON robot to automate standard proteolysis protocols. Dr. Singh has established several innovative mass spectrometry-enabled proteomic concepts including the first soluble full-length stable isotope-labeled amino acid protein standard (FLEXIQuant); HR/AM-MS/MS for stable isotope-mediated apolipoprotein turnover in humans; and RiboMaP, a spectral annotation tool for ADP-ribosylation proteomics. The candidate will have many opportunities to develop additional innovative workflows for his/her project.

CICS was launched in collaboration with Kowa Company Ltd, a Japanese pharmaceutical company. This academia-industry collaboration develops and utilizes state-of-the-art platforms that in part rely on mass spectrometry-based strategies for drug target discovery research. We conduct interdisciplinary, team-driven research with scientists from Brigham and Women’s Hospital and Kowa working together in a shared space. Our intent is to establish a diverse, active and innovative working environment. CICS occupies a fully equipped 25,000-sq.ft. space on the 17th floor of the Center for Life Sciences in the Longwood Medical Area, the heart of Boston’s medical and research community. Please visit our website at http://cics.bwh.harvard.edu for further information about our center.